Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Clinical and Translational Science|March 3, 2026
Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice ServiceYoussef Libiad, Bénédicte Franck, Camille Tron, et al.
Therapeutic Drug Monitoring|December 2, 2024
One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn DiseaseBénédicte Franck, Camille Tron, Marie-Clémence Verdier, et al.
Therapeutic Drug Monitoring|July 13, 2017
Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate MofetilFlorian Lemaitre, Zeineb Ben Ali, Camille Tron, et al.
Clinical Pharmacology and Therapeutics|March 13, 2019
Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel DiseasesAntoine Petitcollin, Charlène Brochard, Laurent Siproudhis, et al.
The British Journal of Dermatology|February 10, 2023
The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanomaFlorence Poizeau, Frédéric Balusson, Florian Lemaitre, et al.
Inflammatory Bowel Diseases|May 23, 2018
Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot StudyAntoine Petitcollin, Oriane Leuret, Camille Tron, et al.
Biomedical Chromatography : BMC|July 2, 2021
Determination of amoxicillin and cotrimoxazole concentrations in sputum of patients with cystic fibrosisCamille Tron, Chantal Belleguic, Caroline Piau, et al.
Pageof 5